VIB spin-off Confo Therapeutics Announces Global Licensing Agreement with Lilly for Peripheral Pain Candidate, CFTX-1554

Lilly will continue the clinical development program beyond Phase 1

VIB spin-off company Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced a worldwide licensing agreement with Eli Lilly and Company for Confo’s clinical stage CFTX-1554 and back-up compounds.

CFTX-1554, a novel inhibitor of the angiotensin II type 2 receptor (AT2R) currently in Phase 1 clinical development, represents a non-opioid approach to treating neuropathic pain, a devastating condition caused by damage to the nerves outside of the brain and spinal cord, and potentially additional peripheral pain indications. Current treatment methods are often insufficiently effective and can lead to serious side effects including addiction. Patients suffering from peripheral pain are therefore in urgent need of effective analgesics that are well-tolerated and do not impact quality of life.

Under the terms of the agreement, Lilly will continue the clinical development program beyond Phase 1. In addition, the agreement considers a program to further develop Confo’s existing therapeutic antibody candidates targeting the same receptor.

"We are pleased that Lilly, an expert in chronic pain with a wealth of experience in bringing novel therapies to patients, has recognized Confo’s ability to develop best-in-class GPCR drug candidates,” said Cedric Ververken, CEO of Confo Therapeutics. “CFTX-1554’s progression through the clinic will benefit from Lilly’s experience and global organization, while we will continue to develop and expand our growing, innovative pipeline of GPCR-targeted assets, both small molecules and biologics.”
Lies Vanneste

Lies Vanneste

Investor Relations Manager, VIB

 

Share

Latest stories

Website preview
MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-based Biotherapeutic Product Pipeline
Ghent, Belgium – September 04, 2025 – MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced the successful closing of a €55 million (US$64 million) Series B financing round.
press.vib.be
Website preview
Spica Therapeutics Secures €1 Million VLAIO Grant to Advance Groundbreaking Macrophage-Targeted Cancer Therapy
Antwerp, Belgium - 27 August, 2025 - Spica Therapeutics, a pioneering biotech company focused on harnessing macrophage biology to develop transformative therapies across multiple disease areas, announced today that it has been awarded a €1.0 million grant from Flanders Innovation & Entrepreneurship (VLAIO).
press.vib.be
Website preview
Scientists map dendritic cell reactions to vaccines 
Ghent, 26 August 2025 – Belgian scientists have uncovered new details about how the immune system responds to vaccines. Dendritic cells, which are key immune messengers that help kick-start the body’s defenses, show specific responses to lipid nanoparticles. These findings, published in Cell Reports, could lead to safer and more effective vaccines.  
press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be